Europe The 2024 combination of 3P Biopharmaceuticals and Biovian gives 3PBIOVIAN greater scale and a broader technology base as Dámaso Molero Sánchez looks towards the CDMO’s next phase of growth. He sets out the rationale behind investments in microbial, mammalian and advanced-therapy manufacturing, explains why the US is becoming central to…
USA Innovators should hold CDMOs to a high bar, and CDMOs need to step up Syed T. Husain, Chairman & CEO of Made Scientific, outlines the organization’s differentiated strategy to disrupt cell therapy manufacturing through a focused, scalable CDMO model. He highlights the company’s Princeton facility, flexible client partnerships, workforce development…
Germany The biggest opportunity is to dare more, invest in promising ideas and become better at translating our excellent science into successful businesses Germany has no shortage of scientific expertise, but turning that research into companies, clinical programmes and ultimately medicines remains a persistent challenge. From its Berlin base, ProBioGen sits…
Global The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for just 15 percent of total revenues. Beyond these giants, a huge network of smaller, more specialised CDMOs are, in…
Germany Our manufacturing base may be local, but the customers we serve and the products we manufacture are truly global Building on decades of microbial manufacturing expertise, Richter BioLogics is scaling its specialised CDMO model through expanded capacity in Germany and a growing international business. Managing Director Dr Kai Pohlmeyer discusses…
Germany Axolabs has spent more than two decades building expertise in a field that is only now beginning to reach greater clinical and commercial scale. Under CEO Susanne Leonhartsberger, the specialist oligonucleotide CRDMO is bringing that scientific heritage together with a substantially expanded manufacturing footprint, including its major new facility in…
Germany I want Wacker Biotech to be recognised for its scientific expertise, speed, collaboration, and flexibility The expectations placed on today’s CDMOs extend far beyond manufacturing capacity, demanding scientific expertise, integrated development capabilities and resilient supply networks capable of supporting increasingly complex therapies. Wacker Biotech has responded by building a distinctive…
Korea James Park discusses Lotte Biologics’ strategy to establish itself as a global CDMO through dual manufacturing hubs in the US and Korea, advanced biologics and ADC capabilities, and a strong service-oriented culture. He outlines the company’s expansion plans, technological differentiation, and support for Korea’s emerging biotech ecosystem, while reflecting on…
Taiwan Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through the state-backed TSMC (Taiwan Semiconductor Manufacturing Company), the island functions as the world’s foundry, manufacturing the advanced chips designed by…
Taiwan With US-China geopolitical tensions pushing multinational pharma to seek manufacturing bases outside China, does Taiwan’s CDMO sector offer a compelling alternative? Recent US policy moves could reshape the global pharmaceutical supply chain. Most significantly, by blocking any company that receives federal funding or government contracts from using ‘high-risk’ Chinese…
Taiwan Lee-Cheng (LC) Liu, CEO of EirGenix, reflects on the evolution of Taiwan’s biotech sector and the company’s role within it as both a biologics CDMO and biosimilar developer. Liu discusses government-backed manufacturing initiatives, shifting global supply chains, and how regulatory changes are reshaping the biosimilar landscape. He also outlines EirGenix’s…
Taiwan As global pharmaceutical companies diversify their manufacturing networks and seek trusted development partners, Taiwan’s CDMO sector is moving into sharper international focus. Drawing on decades of experience building ScinoPharm into a globally recognised API supplier, Jo Shen discusses the evolution of Taiwan’s life sciences ecosystem, the creation of the Taiwan…
See our Cookie Privacy Policy Here
